Companies › Innate Pharma
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IPH5201 TriFaRed-Ig antibody (IgG4 Fc-silenced anti-BTLA monoclonal antibody) | – | Phase 2 | Non Small Cell Lung Cancer | Jun 2027 |
| IPH4502 Nectin-4-directed antibody-drug conjugate (ADC) | NECTIN4 | Phase 1 | Advanced or Metastatic Solid Tumors | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05742607 | IPH5201 | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT06781983 | IPH4502 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Apr 2028 |
Cash and short-term investments of 34m EUR on 2025-12-31; operating cash outflow about 53m EUR a year; runway about 8 months at that burn, to Aug 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Tianjin ConjuStar Biologics Radiopharm Theranostics Dogwood Therapeutics Atossa Therapeutics Curis
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.